Cambrex
- Company typePrivate
- Founded1980
- HeadquartersEast Rutherford, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Cambrex firmographics
Firmographics- Name
- Cambrex
- Legal name
- Cambrex Corporation
- Website
- https://cambrex.com
- Company type
- Private
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Cambrex industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Cambrex is headquartered
LocationHeadquarters
- HQ city
- East Rutherford
- HQ country
- United States
- HQ region
- North America
Offices10 records
Markets served
Cambrex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Drug Substance Development and Manufacturing: Custom API development and manufacturing services including process development, scale-up, and commercial manufacturing. Revenue generated through project-based contracts, development fees, manufacturing fees, and potentially milestone payments tied to clinical and regulatory milestones.
- Generic API Manufacturing: Supply of generic active pharmaceutical ingredients from catalog products and custom manufacturing. Revenue from product sales of generic APIs, intermediates, derivatives, and chiral compounds.
- Analytical Services: Comprehensive analytical testing and characterization services including method development, validation, stability testing, and microbiology services.
- Drug Product Services: Formulation development and clinical trial manufacturing services from early-phase through commercial scale, including tablet and capsule manufacturing.
- Stability Storage Services (via Q1 Scientific): Pharmaceutical stability storage and sample management services through Q1 Scientific subsidiary.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Cambrex product offering
Product offeringCore offering
Cambrex is a global contract development and manufacturing organization (CDMO) that develops and manufactures active pharmaceutical ingredients (APIs) and drug products for pharmaceutical and biotech clients. The company provides end-to-end drug substance services (custom and generic API development and manufacturing, peptides, HPAPIs, controlled substances, biocatalysis, continuous flow), drug product services (oral solid dose formulation and clinical trial manufacturing), and analytical services (method development, stability testing, microbiology) across facilities in North America and Europe.
Product overview
Cambrex is a global contract development and manufacturing organization (CDMO) offering integrated drug substance and drug product services across the entire drug lifecycle. The portfolio is organized around three core pillars: Drug Substance Services (custom API development and manufacturing, generic APIs, specialty solutions including continuous flow, biocatalysis, HPAPIs, controlled substances, and complex synthetics), Analytical Services (comprehensive testing, solid state chemistry, stability storage via Q1 Scientific subsidiary, and microbiology), and Drug Product Services (formulation development and clinical trial manufacturing). The company has expanded capabilities through acquisitions including Snapdragon Chemistry (flow chemistry, custom peptides, complex synthetics, proprietary Z-Flow™ LPPS technology and LabOS platform for automated process development) and Q1 Scientific (stability storage). Services span from early-phase IND enabling through commercial manufacturing, covering over 90 generic APIs, controlled substances, and specialized peptide/oligonucleotide manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- Snapdragon Chemistry: Specialized process development, flow chemistry, GMP manufacturing, custom peptide synthesis, complex synthetics, continuous process technologies, and reactor build and design services.
- Q1 Scientific
Products and services
- Drug Substance Services Comprehensive drug substance development and manufacturing services including custom API development, custom API manufacturing, generic API manufacturing, and specialty solutions (biocatalysis, continuous flow, highly potent APIs, controlled substances, complex synthetics, crystallization) for pharmaceutical and biotech clients.
- Analytical Services Full suite of analytical testing services including method development and validation, release and ICH stability testing, material characterization, elemental impurities, compendial testing, impurity identification, nitrosamine testing, extractables and leachables testing, and reference standards.
- Drug Product Services Drug product development and manufacturing including formulation development and clinical trial manufacturing for oral solid dose formulations (tablets, capsules) at early through late phases for pharmaceutical clients.
- Generic API Manufacturing Leading global supplier of generic APIs from sites in Italy, Sweden, and the USA. Portfolio of over 90 generic APIs, intermediates, derivatives, and chiral compounds including controlled substances, serving generic pharmaceutical firms requiring off-patent API supply.
- Peptide Development and Manufacturing Cutting-edge peptide development and manufacturing combining solid phase synthesis (SPPS) and liquid phase peptide synthesis (LPPS) capabilities for early-stage clinical development through large-scale GMP manufacturing, meeting growing demand for peptide-based therapeutics.
- Snapdragon Chemistry Services Specialized chemistry solutions provider offering process development, GMP manufacturing, flow chemistry, custom peptide synthesis, complex synthetics, and reactor build and design services using advanced software and equipment for biopharmaceutical clients.
- Q1 Scientific Stability Storage Stability storage and sample management company providing pharmaceutical storage conditions meeting ICH Q1A requirements through walk-in and reach-in chambers for pharmaceutical and medical device companies.
Quantifiable outcome
- Process mass intensity reduced by approximately 80% in organocatalytic process for obicetrapib
- +4 more outcomes
Companies that use Cambrex
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Cambrex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature7 records
Cambrex partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- NewAmsterdam PharmacoreCollaboration on development of sustainable organocatalytic process for obicetrapib, resulting in American Chemical Society Green Chemistry Challenge Award. Achieved 80% PMI reduction, 70% cycle time reduction, and 50% cost reduction in manufacturing.
- Alexion PharmaceuticalscoreTechnology transfer and process development collaboration for danicopan, a complement Factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Included significant process improvements in yield, PMI, and cycle times.
- Q1 ScientificcoreCambrex company providing stability storage and sample management capabilities. Q1 Scientific offers pharmaceutical storage conditions meeting ICH Q1A requirements through walk-in and reach-in chambers.
- FlogasminorCorporate Power Purchase Agreement (CPPA) partnership through Q1 Scientific to source renewable electricity from Cronalaght Wind Farm, covering approximately 50% of Waterford site electricity demand.
- Snapdragon ChemistrycoreAcquired by Cambrex, Snapdragon operates as a Cambrex company specializing in process development, continuous flow chemistry, and advanced manufacturing technologies including Z-Flow LPPS.
- SanoficoreCo-authored study on RIPK1 inhibitor oditrasertib demonstrating continuous flow manufacturing process for pharmaceutical production.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Cambrex competitors and assessment
Company assessmentDirect peers
- Lonza Group: Global CDMO offering drug substance and drug product services across small molecules, peptides, and biologics. Most directly comparable to Cambrex as a leading one-stop-shop CDMO serving pharma and biotech customers.
- Catalent: Major CDMO with drug substance, drug product, and clinical supply capabilities. Comparable to Cambrex in providing integrated development and manufacturing services to large pharma and biotech clients.
- Siegfried Holding: Swiss-based CDMO specializing in small-molecule API manufacturing and drug product services. Highly comparable to Cambrex's custom API, generic API, and oral solid dose drug product offerings.
- Recipharm: European CDMO with API and drug product manufacturing capabilities. Comparable to Cambrex as a mid-sized CDMO serving both innovator and generic pharma customers.
- WuXi AppTec: Global CRO/CDMO with extensive small-molecule and biologics capabilities. A peer across the drug development and manufacturing value chain, particularly for biotech customers.
- Bachem: Specialist CDMO in peptide and oligonucleotide API manufacturing. Most directly comparable to Cambrex's peptide platform (Z-Flow LPPS) and incremental peptide capacity at Karlskoga.
Broad incumbents
- Thermo Fisher Scientific (CDMO/Patheon): Through Patheon and its pharma services division, Thermo Fisher offers comprehensive CDMO services including API, drug product, and clinical supply. A scaled, diverse incumbent competing with Cambrex across drug substance and drug product.
- Charles River Laboratories: Provides discovery, preclinical, and manufacturing services to pharma and biotech. Overlaps with Cambrex in analytical and drug substance support and competes for biotech development budgets.
Others
- Eurofins Scientific: Global laboratory testing services provider with strong pharma/biopharma analytical and CMC testing capabilities. Comparable to Cambrex's analytical services and Q1 Scientific stability storage offerings.
Emerging players
- Samsung Biologics: South Korea-based large-scale CDMO expanding from biologics into synthetic and oligonucleotide manufacturing. An emerging adjacency to Cambrex in the contract API manufacturing space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cambrex social profiles
Digital presenceCambrex compliance and trust
Trust signalCompliance15 records
Cambrex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cambrex leadership team
Management profileNumber of profiles
Profiles8 records
Cambrex subsidiaries and ownership
Company hierarchySubsidiaries2 records
Cambrex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cambrex M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cambrex
What does Cambrex do?
Cambrex is a global contract development and manufacturing organization (CDMO) that develops and manufactures active pharmaceutical ingredients (APIs) and drug products for pharmaceutical and biotech clients. The company provides end-to-end drug substance services (custom and generic API development and manufacturing, peptides, HPAPIs, controlled substances, biocatalysis, continuous flow), drug product services (oral solid dose formulation and clinical trial manufacturing), and analytical services (method development, stability testing, microbiology) across facilities in North America and Europe.
Is Cambrex a public or private company?
Cambrex is a private company. It is classified as unknown and is currently operating.
When was Cambrex founded?
Cambrex was founded in 1980. It employs 1,001 to 5,000 people.
Where is Cambrex based?
Cambrex is headquartered in East Rutherford, United States, in the North America region.
How does Cambrex make money?
Five revenue lines are on record. Drug Substance Development and Manufacturing is the primary driver. The others are generic API Manufacturing, analytical Services, drug Product Services and stability Storage Services (via Q1 Scientific).
Who are Cambrex's main competitors?
Direct peers on record are Lonza Group, Catalent, Siegfried Holding, Recipharm, WuXi AppTec and Bachem. Broad incumbents are Thermo Fisher Scientific (CDMO/Patheon) and Charles River Laboratories. Eurofins Scientific is listed as an others. Samsung Biologics is listed as an emerging player.
Does Cambrex have an API?
No public API is recorded for Cambrex.
What industry is Cambrex in?
Cambrex's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325411 and its SIC code is 2834.